REG - Induction Healthcare - Update on NHS National Portals Contracts

Induction HealthcareAnnouncement

10/10/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20231010:nRSJ0296Pa&default-theme=true

RNS Number : 0296P  Induction Healthcare Group PLC   10 October 2023

Induction Healthcare Group PLC

("Induction", the "Company", or the "Group")

 

Update on NHS National Portals Contracts

 

Induction (AIM: INHC), a leading digital health platform driving
transformation of healthcare systems, provides an update on recent contracts
wins with the NHS.

 

Induction has recently signed three new patient portal development contracts
totaling £1.4m:

 

·      North Central London ICS (covering three Trusts) worth £486,000
enabling patients, through the Zesty patient portal, to view their diagnostic
appointment details as well as launch an Attend Anywhere video consultation.

 

·      Royal Free London worth £346,000 covering several patient portal
projects including the use of Induction's Form Builder module for wait list
validation and enhancing functionality for Patient Initiated Follow Up (PIFU),
an initiative seen by the NHS as being vital in reducing the backlog.
Induction will also be working with the Royal Free and other customers to be
the first NHS-accredited portal to digitize maternity records for expectant
mothers and ensure the records are accessible within Zesty.

 

·      South West London ICB worth £577,000 covering several patient
portal projects which also includes the use of the Form Builder module for
waitlist validation. These projects will also deepen Induction's bespoke
integration with Oracle Health to enable data to be written back to the
hospital system, reducing the data processing administrative burden on Trusts.

 

Induction CEO, Paul Tambeau, said: "These development and supply contracts
demonstrate Induction's growing traction in the patient platform market as we
work with the NHS to give patients more choice in how their care is managed.
It also validates our strategy of integrating our Attend Anywhere video
consultation and our Zesty patient portal platforms. These contracts also
allow Induction to introduce new appointment types and to further deepen our
technical integration with partners. We are also proud to be the first
NHS-accredited portal provider in the UK to digitize maternity records and
make it easier for expectant mothers to access their records.

 

Induction is currently negotiating additional contracts across the NHS and we
look forward to providing further updates at the time of our Interim results
which will be published on 7 November 2023.

 

 

Enquiries

 

 Induction

 Christopher Samler, Chair                              +44 (0)7712 194092

 Paul Tambeau, Chief Executive Officer                  +44 (0)7983 104443

 Singer Capital Markets (Nominated Adviser and Broker)  +44 (0)20 7496 3000
 Philip Davies, Alaina Wong

 

About Induction - www.inductionhealthcare.com
(http://www.inductionhealthcare.com/)

Induction (AIM: INHC) delivers a suite of software solutions through a single
integrated platform that transforms care delivery. Our system-wide
applications help healthcare providers and administrators to deliver care at
any stage remotely as well as face-to-face - giving the communities they serve
greater flexibility, control and ease of access. Purpose-built for integration
with leading Electronic Medical Record (EMR) platforms, our products offer
immediate stand-alone value that becomes even greater when integrated with
pre-existing systems.

 

Used at scale by national and regional healthcare systems, as well non-health
government services, our applications are relied upon by hundreds of thousands
of clinicians and millions of patients across almost every hospital in the
British Isles.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  UPDUNUSROAURRAA